Other

Mobay Corporation

Miles Laboratories, Inc.

Dermal Research Laboratories, Inc.

Akzo Nobel N.v.

Phibro Animal Health Corporation

Bayer Corporation

Miles Inc.

Intervet International B.v.

Cutter Laboratories, Inc.

Akzo Nobel

Dermal Reserach Laboratories, Inc.

Karen K Brown

Sharon A Bryant

Kristina J Hennessy

Ronald C Montelaro

Harold G Brown

Bridget Puffer

Charles Issel

Carol A Cooper

Boh Chang Lin

Wesley W Johnson

Michael Dennis Murphy

Jeffrey Alan Kula

Nathan D Greene

Feng Li

Grant Weaver

Richard C Stewart

Richard E Parizek

Jennifer K Lane

Sandra L Trump

Sandy L Trump

Ivo Van De Rijn

Jodi Craigo

Kristina J Hennessey

Linda L Ruiz

George P Shibley

Louis J Travalent

John O Mozier

Kenneth S Lewis

Terry H Wollen

Richard H Schultz

Leszek J Choromanski

Larry F Moore

Curtis D Wilson

Bobby O Moore

Joseph Macek

The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning forinfections and between four and six weeks post-weaning forandinfections. Clinical disease control associated withandhas been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant. The composition may be administered to subjects, such as animals, particularly piglets from pre-weaning through the nursery phase, such as from birth or from three to five days of age, to protect from these diseases.

Composition comprising antigens and a mucosal adjuvant and a method for using

An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule.

Hyaluronic acid stabilizer

An embodiment of the present disclosure provides a composition that includes hyaluronic acid, or its salt or derivative thereof, zinc citrate and an additive selected from the group consisting of grapefruit seed extract, Citricidal&#x2122;, calcium propionate, sodium benzoate, potassium benzoate, magnesium citrate, proline, raddish root extract, Leucidal&#x2122; or 1,2-propanediol.

The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades.

Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same

The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of at least one low purity or cosmetic grade complex carbohydrate selected from the group consisting of oligosaccharides, sialylated oligosaccharides, polysaccharides and glycosaminoglycans, and an effective amount of at least one transdermal or transmucosal carrier in an amount effective to deliver the complex carbohydrate into the blood stream.

Methods of preventing or treating diseases and conditions using complex carbohydrates

A process for making an adjuvanted vaccine comprising host albumin. The process comprises mixing host serum or host serum with an antigen, and then mixing the resulting mixture with an adjuvant.

Process for making an adjuvanted vaccine comprising host albumin

Avaccine comprising tissue culture grownand methods of making and using said vaccines.vaccines described include those containing wholetachyzoites, extracts oftachyzoites and protective antigen subunits oftachyzoites. The vaccines of this invention may be in a liquid or lyophilized form.

[object Object]

The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

EIA vaccine and diagnostic

The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.

Growing community of inventors

Parkville, MO, United States of America

Karen K Brown